Parkinson's disease patients moving from levodopa-carbidopa
treatment to Azilect or adding Azilect to their levodopa-carbidopa
therapy likely need additional treatment to control motor symptoms.
Continuous intraoral administration of levodopa-carbidopa
reduced variability in plasma levodopa concentrations and reduced OFF time associated with Parkinson's disease
Parkinsons Disease: A therapy that is a once-daily, transdermal formulation of levodopa-carbidopa
NASDAQ: IPXL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending that NUMIENT (IPX066), a modified-release oral capsule formulation of levodopa-carbidopa
, be granted approval for the symptomatic treatment of adult patients with Parkinson's disease.
Effects of levodopa-carbidopa
intestinal gel on non-motor symptoms and safety of outpatient titration: a new phase 3 study in patients with advanced Parkinson's disease; Standaert, DG, et al.
Interim Results of a Phase 3b Study Assessing the Safety and Efficacy of Levodopa-Carbidopa
Intestinal Gel on Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease; Dubow, J.
DUBLIN, June 18, 2012 /PRNewswire/ -- Today Abbott (NYSE: ABT) announced results from five abstracts evaluating levodopa-carbidopa
intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease.
The trial tested standard oral dosages of a Parkinson's drug against the newer levodopa-carbidopa
intestinal gel (LCIG) and found that the intestinal treatments gave patients an average of two extra hours per day of reduced symptoms and improved movement.
April 17, 2012 /PRNewswire/ --Abbott (NYSE: ABT) announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa
intestinal gel (LCIG).
NEW ORLEANS, April 17, 2012 /PRNewswire-USNewswire/ --A levodopa-carbidopa
intestinal gel (LCIG) works better than standard oral levodopa-carbidopa
in reducing "off" time in patients with advanced Parkinson's disease.
In a 54-week study, after 12 weeks of treatment with levodopa-carbidopa
intestinal gel, patients reported improvement in motor symptoms
About Half of Surveyed Neurologists Say They Will Increasingly Delay Their Use of Levodopa-Carbidopa
in the Next Two Years, According to a New Report from Decision Resources